Telix agreed to acquire ITM after the FDA issued a complete response letter for ITM-11.
Why it matters: The deal links a regulatory setback to consolidation in radiopharma, where manufacturing capacity and late-stage assets influence valuation. It also gives investors a clearer read on how quickly biotech M&A can follow an FDA decision.
- Telix announced the merger with ITM on Sept. 21, 2026, valuing the deal at at least $1.65 billion on a debt-free, cash-free basis.
- ITM shareholders are expected to receive about $1.25 billion in Telix shares, plus up to $700 million in contingent payments tied to ITM-11 milestones.
- The FDA issued ITM a complete response letter on Aug. 7, 2026, citing chemistry, manufacturing and controls issues and third-party facility inspection issues.
- ITM said the FDA did not raise clinical safety or efficacy concerns and did not request additional clinical or nonclinical data.
Telix Pharmaceuticals and ITM Isotope Technologies Munich SE said they will combine in a merger valued at least $1.65 billion, following ITM's disclosure of an FDA complete response letter for its lead radiopharma candidate. Telix's announcement said the companies expect the deal to close by the end of Telix's FY 2026, subject to shareholder approval, regulatory approvals and other customary conditions.
The companies said the combination will link Telix's commercial oncology platform with ITM's isotope-production and radiopharmaceutical-development capabilities. Telix said ITM supplies therapeutic radioisotopes including lutetium-177, actinium-225 and terbium-161. ITM's release said the FDA's Aug. 7 letter for ITM-11, or 177Lu-edotreotide, cited chemistry, manufacturing and controls and third-party commercial facility inspection-related issues, but did not identify clinical safety or efficacy concerns.
ITM said its COMPETE Phase 3 trial met its primary endpoint, while the COMPOSE Phase 3 study is ongoing and expected to read out in H1 2027. Under the merger terms, ITM shareholders would receive about $1.25 billion in Telix shares, plus up to $700 million in contingent consideration tied to regulatory approvals and commercial sales milestones for ITM-11.
By the numbers
- $1.65 billion - minimum deal value on a debt-free, cash-free basis
- $1.25 billion - value of Telix shares ITM holders are expected to receive
- $700 million - contingent consideration tied to ITM-11 milestones
Yes, but: The merger still needs shareholder and regulatory approvals, and the transaction terms include contingent payments tied to future regulatory and sales milestones.
What's next: The companies said they expect the deal to close by the end of Telix's FY 2026, subject to approvals and other customary conditions.